A systematic review and meta‐analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections

Isavuconazole is a novel triazole antifungal agent. However, the previous outcomes were highlighted by statistical heterogeneity. This meta‐analysis aimed to validate the efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections (IFIs) compared with other antifungal agents (amphotericin B, voriconazole and posaconazole).

[1]  S. Kimura,et al.  Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. , 2022, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  I. Morrissey,et al.  In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China , 2022, Infection and drug resistance.

[3]  T. Kadia,et al.  Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  T. Iwamoto,et al.  A Systematic Review and Meta-Analysis of Efficacy and Safety of Azithromycin Versus Moxifloxacin for the Initial Treatment of Mycoplasma genitalium Infection , 2022, Antibiotics.

[5]  T. Iwamoto,et al.  Systematic review and meta-analysis for impacts of oral antibiotic treatment on pregnancy outcomes in chronic endometritis patients. , 2022, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  T. Iwamoto,et al.  Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: A systematic review and meta-analysis. , 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  R. Jørgensen,et al.  Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole , 2021, Antibiotics.

[8]  R. Rivosecchi,et al.  Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  I. Solomon,et al.  Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis , 2020, Mycoses.

[10]  D. Dilling,et al.  Advances in the Diagnosis and Management of Invasive Fungal Disease. , 2019, Chest.

[11]  E. Esterberg,et al.  Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study , 2019, Infectious Diseases and Therapy.

[12]  R. MacLaren,et al.  Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center , 2019, Annals of Clinical Microbiology and Antimicrobials.

[13]  M. Hoenigl,et al.  Broad spectrum triazoles for invasive mould infections in adults: Which drug and when? , 2019, Medical mycology.

[14]  D. Kuessner,et al.  Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden , 2019, BMC Infectious Diseases.

[15]  C. Moore,et al.  Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events , 2019, Mycoses.

[16]  S. Koo,et al.  358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA) , 2018, Open Forum Infectious Diseases.

[17]  P. Bonate,et al.  Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi , 2017, Antimicrobial Agents and Chemotherapy.

[18]  E. Wu,et al.  Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis , 2016, Advances in Therapy.

[19]  J. Perfect,et al.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.

[20]  P. Bonate,et al.  Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. , 2016, The Journal of antimicrobial chemotherapy.

[21]  J. Baddley,et al.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.

[22]  T. Walsh,et al.  Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis , 2016, Antimicrobial Agents and Chemotherapy.

[23]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  P. Ljungman,et al.  Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005–2009) , 2015, Mycoses.

[25]  Marisa H Miceli,et al.  Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Turnidge,et al.  Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth Microdilution Method , 2014, Antimicrobial Agents and Chemotherapy.

[27]  P. Grossi,et al.  Invasive fungal infections in solid organ transplant recipients. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  D. Enoch,et al.  Micafungin for the treatment of invasive aspergillosis. , 2014, The Journal of infection.

[29]  L. Pagano,et al.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  A. Ibrahim,et al.  Isavuconazole Therapy Protects Immunosuppressed Mice from Mucormycosis , 2014, Antimicrobial Agents and Chemotherapy.

[31]  D. Andes,et al.  Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus , 2013, Antimicrobial Agents and Chemotherapy.

[32]  D. Andes,et al.  Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model , 2013, Antimicrobial Agents and Chemotherapy.

[33]  David W. Denning,et al.  Hidden Killers: Human Fungal Infections , 2012, Science Translational Medicine.

[34]  F. Aversa,et al.  Voriconazole in clinical practice , 2012, Journal of chemotherapy.

[35]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[36]  F. Lanternier,et al.  Liposomal amphotericin B: what is its role in 2008? , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[37]  N. Black,et al.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.

[38]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[39]  P. Chandrasekar,et al.  Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations , 2016, Infection and drug resistance.

[40]  Guidance for Industry Clinical Pharmacogenomics : Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling , 2013 .

[41]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.